J&J Raises Outlook, Lowers Tariff Cost After Q2 Beat

Johnson & Johnson exceeded Wall Street expectations for both profit and revenue in the second quarter of 2025, reporting sales of $23.74 billion and adjusted EPS of $2.77. The company raised its full-year 2025 sales guidance to $93.2–$93.6 billion and increased its adjusted EPS outlook to $10.80–$10.90. J&J lowered its projected tariff-related costs for 2025 to $200 million from $400 million after the Trump administration paused new tariffs on China, benefiting primarily the medical device division. Strong demand for the cancer drug Darzalex and a 6.1% sales rise in the medtech segment contributed to the results. The company’s strong performance comes amid ongoing regulatory and tariff uncertainty in the pharmaceutical industry. J&J's ability to raise guidance while absorbing tariff costs highlights its operational resilience.